BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 15106079)

  • 1. [A modified ultra-rush-protocol of allergen immunotherapy in children and adolescents with insect venom allergy].
    Steiss JO; Hüls G; Gortner L; Lindemann H
    Klin Padiatr; 2004; 216(2):79-82. PubMed ID: 15106079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A modified ultrarush insect venom immunotherapy protocol for children.
    Steiss JO; Jödicke B; Lindemann H
    Allergy Asthma Proc; 2006; 27(2):148-50. PubMed ID: 16724635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific ultrarush desensitization in Hymenoptera venom-allergic patients.
    Schiavino D; Nucera E; Pollastrini E; De Pasquale T; Buonomo A; Bartolozzi F; Lombardo C; Roncallo C; Patriarca G
    Ann Allergy Asthma Immunol; 2004 Apr; 92(4):409-13. PubMed ID: 15104191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Three days rush venom immunotherapy in bee allergy: safe, inexpensive and instantaneously effective.
    Goldberg A; Yogev A; Confino-Cohen R
    Int Arch Allergy Immunol; 2011; 156(1):90-8. PubMed ID: 21447964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maintenance venom immunotherapy administered at 3-month intervals is both safe and efficacious.
    Goldberg A; Confino-Cohen R
    J Allergy Clin Immunol; 2001 May; 107(5):902-6. PubMed ID: 11344360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Results of hyposensitization with bee and wasp venom].
    Adolph J; Dehnert I; Fischer JF; Wenz W
    Z Erkr Atmungsorgane; 1986; 166(1):119-24. PubMed ID: 3953108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of specific immunotherapy using a four-hour ultra-rush induction scheme in bee and wasp allergy.
    Roll A; Hofbauer G; Ballmer-Weber BK; Schmid-Grendelmeier P
    J Investig Allergol Clin Immunol; 2006; 16(2):79-85. PubMed ID: 16689180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of safety, risk factors and pretreatment methods during rush hymenoptera venom immunotherapy.
    Gorska L; Chelminska M; Kuziemski K; Skrzypski M; Niedoszytko M; Damps-Konstanska I; Szymanowska A; Siemińska A; Wajda B; Drozdowska A; Jutel M; Jassem E
    Int Arch Allergy Immunol; 2008; 147(3):241-5. PubMed ID: 18594155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid venom immunotherapy is safe for routine use in the treatment of patients with Hymenoptera anaphylaxis.
    Bernstein JA; Kagen SL; Bernstein DI; Bernstein IL
    Ann Allergy; 1994 Nov; 73(5):423-8. PubMed ID: 7978535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Accelerated desensitization for hymenoptera venom allergy in 30 hours: efficacy and safety in 150 cases].
    van der Brempt X; Ledent C; Mairesse M
    Rev Med Brux; 1997 Jun; 18(3):120-4. PubMed ID: 9273600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The value of immunotherapy with venom in children with allergy to insect stings.
    Valentine MD; Schuberth KC; Kagey-Sobotka A; Graft DF; Kwiterovich KA; Szklo M; Lichtenstein LM
    N Engl J Med; 1990 Dec; 323(23):1601-3. PubMed ID: 2098016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Immunotherapy against hymenoptera venom: report of ten patients].
    Guzmán M MA; Salinas L J; Toche P P; Marinovic M MA; Gallardo O AM
    Rev Med Chil; 2007 Dec; 135(12):1566-71. PubMed ID: 18357358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Venom immunotherapy: tolerance to a 3-day protocol of rush-immunotherapy.
    Díez Gómez ML; Quirce Gancedo S; Juliá de Páramo B
    Allergol Immunopathol (Madr); 1995; 23(6):277-84. PubMed ID: 8579006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rush venom immunotherapy in patients experiencing recurrent systemic reactions to conventional venom immunotherapy.
    Goldberg A; Confino-Cohen R
    Ann Allergy Asthma Immunol; 2003 Oct; 91(4):405-10. PubMed ID: 14582821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of rush insect venom immunotherapy. The results of a retrospective study in 178 patients.
    Wenzel J; Meissner-Kraemer M; Bauer R; Bieber T; Gerdsen R
    Allergy; 2003 Nov; 58(11):1176-9. PubMed ID: 14616130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Therapy control of specific hymenoptera venom allergy].
    Aust W; Wichmann G; Dietz A
    Laryngorhinootologie; 2010 Dec; 89(12):725-8. PubMed ID: 21132618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of allergy to insect stings in children, with and without venom immunotherapy.
    Golden DB; Kagey-Sobotka A; Norman PS; Hamilton RG; Lichtenstein LM
    N Engl J Med; 2004 Aug; 351(7):668-74. PubMed ID: 15306668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Efficacy of a Progressively Prolonged Maintenance Interval of Venom Immunotherapy.
    Kontou-Fili K; Pitsios C; Kompoti E; Giannakopoulos D; Kouridakis S
    Int Arch Allergy Immunol; 2018; 176(1):39-43. PubMed ID: 29649812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene expression analysis in predicting the effectiveness of insect venom immunotherapy.
    Niedoszytko M; Bruinenberg M; de Monchy J; Wijmenga C; Platteel M; Jassem E; Oude Elberink JN
    J Allergy Clin Immunol; 2010 May; 125(5):1092-7. PubMed ID: 20334904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expansion of circulating Foxp3+)D25bright CD4+ T cells during specific venom immunotherapy.
    Pereira-Santos MC; Baptista AP; Melo A; Alves RR; Soares RS; Pedro E; Pereira-Barbosa M; Victorino RM; Sousa AE
    Clin Exp Allergy; 2008 Feb; 38(2):291-7. PubMed ID: 18070166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.